Thorne Research, Niasafe-600 180 capsules

SKU# TR-B114

Availability: Out of stock

$49.30
Niacin has long been prescribed for the treatment of various cardiovascular conditions, particularly hyperlipidemia. It has been proven effective at lowering VLDL, LDL, total cholesterol, and triglyceride levels, while raising HDL levels. The side effects of niacin that may occur at the dosages often required for therapeutic efficacy, ranging from flushing and pruritis to hepatoxicity and impaired glucose tolerance, often prove troubling for both patient and practitioner.

The need for a safer approach to niacin supplementation resulted in the investigation of niacin esters. One of the most widely studied of these is inositol hexaniacinate (IHN). In numerous trials it has been found to be virtually free of the side effects associated with conventional niacin therapy. Pharmacokinetic studies show the IHN molecule is absorbed intact and slowly hydrolyzed in the bloodstream, with the release of free niacin and inositol. Maximum serum levels are reached approximately 10 hours after ingestion. This allows for a more delayed release of niacin, which reduces the risk of flushing.

Extensive research has found IHN to be effective in the treatment of Raynaud’s disease and intermittent claudication. A review of the literature reveals numerous positive studies on the use of IHN in Raynaud’s disease. The typical dosage is 1 g four times daily for several months. The mechanism of action appears to be more than just a transient vasodilation, involving lipid lowering and fibrinolysis. This explains the need for long-term administration. The use of inositol hexaniacinate for the treatment of intermittent claudication secondary to atherosclerosis has been examined extensively. Significant improvement has been reported by several investigators at dosages of 2 g twice daily, typically for at least three months. While arterial dilation may be a factor, it has been postulated that reduction in fibrinogen, improvement in blood viscosity, and resultant improvement in oxygen transport are involved in the therapeutic effects. IHN appears to have application in the treatment of other conditions resulting from peripheral vascular insufficiency, including restless legs syndrome, stasis dermatitis, atherosclerosis related migraines, and hypertension.
Suggested Use No
Supplement Facts Dosage:1 to 3 capsules tid
Each Capsule Contains DV%
Niacin (from 600 mg Inositol Hexaniacinate*)
510 mg
2550%
Daily Value (DV)
*Does not cause flushing in most patients.
B114/ 180

A woman who is pregnant or nursing, or who might become pregnant, should consult a health-care practitioner before using this product.

SPECIAL NOTE: Use of high-dose niacin is contraindicated in patients with gout
Other Ingredients No
Warnings No
SKU TR-B114
Name Thorne Research, Niasafe-600 180 capsules
UPC 693749114024
Basic Name Niasafe-600 180 capsules
MPN B114
Brand Thorne Research
Form Capsule
Shipping Weight 0.4100
Serving Size 1
Product Type Corn Free, Dairy Free, Egg Free, Gluten Free, Hypoallergenic, Wheat Free, Yeast Free

2 Items

View: 10 / 20 / 50
  • Choleast By rosmar
    Rating
  • Good By rosmar
    Rating
Write Your Own Review

Only registered users can write reviews. Please, log in or register

Questions:

There are no product questions yet.

Please login to your account to post a question

Frequently bought together

Customers who bought this product also commonly purchased the following combination of items.

  •   Thorne Research, Niasafe-600 180 capsules
  •   Integrative Therapeutics, Tyler Similase Lipo 90 Veg Capsules
  •   Nordic Naturals, Ultimate Omega 1,000 mg Lemon 180 softgels

Back to top